scholarly journals Clinical Trial Design and Consequences for Drug Development for Community‐Acquired Pneumonia: An Industry Perspective

2008 ◽  
Vol 47 (S3) ◽  
pp. S237-S240 ◽  
Author(s):  
Glenn S. Tillotson ◽  
Roger M. Echols
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Community Acquired Pneumonia

The future of drug development: advancing clinical trial design

2009 ◽  
Vol 8 (12) ◽  
pp. 949-957 ◽  
Author(s):  
John Orloff ◽  
Frank Douglas ◽  
Jose Pinheiro ◽  
Susan Levinson ◽  
Michael Branson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Trial Design ◽  
Clinical Trial Design ◽  
The Future

scholarly journals Clinical Trial Design for Mild‐to‐Moderate Community‐Acquired Pneumonia—An Industry Perspective

2008 ◽  
Vol 47 (S3) ◽  
pp. S166-S175 ◽  
Author(s):  
Roger M. Echols ◽  
Glenn S. Tillotson ◽  
James X. Song ◽  
Robert L. Tosiello
Keyword(s):  
Clinical Trial ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Community Acquired Pneumonia

scholarly journals Drug development and clinical trial design in pancreatico-biliary malignancies

2018 ◽  
Vol 42 (1) ◽  
pp. 73-94 ◽  
Author(s):  
Jennifer Harrington ◽  
Louise Carter ◽  
Bristi Basu ◽  
Natalie Cook
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Biliary Malignancies

scholarly journals Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology

2016 ◽  
Vol 12 (8) ◽  
pp. e810-e817 ◽  
Author(s):  
Kenneth A. Kern
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Molecular Entity ◽  
Development Programs ◽  
Key Factors ◽  
Us Congress ◽  
Oncology Research ◽  
The Us

Breakthrough therapy designation (BTD) is a new approach created by the US Congress and the US Food and Drug Administration (FDA) as part of the FDA Innovation and Safety Act of 2012 to expedite the drug development process for serious illness, including cancer. By law, to qualify for BTD, a new molecular entity must demonstrate substantial clinical improvement over existing therapies. Although the administrative requirements for granting BTD have been made available by the FDA, the actual trial designs, end points, and quantitative therapeutic thresholds involved in the granting process have not been made public. This literature review evaluates nine oncology new molecular entities granted BTD involved in 10 accelerated approvals and summarizes the key factors in clinical trial design leading to successful BTD applications. This information can be used by oncology research teams to set goals for BTD when developing clinical trial designs and thresholds in expedited drug development programs.

Quantitative groups will be critical to the success of future gene therapy programs

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Clinical Trial ◽  
Gene Therapy ◽  
Drug Development ◽  
Trial Design ◽  
Development Program ◽  
Clinical Trial Design ◽  
Research Quality ◽  
Recent Experience ◽  
Preclinical Research ◽  
Medical Needs

To maximize the odds of success of a novel drug development program, we must understand the PK, safety profile, and PD potential of the chemical as soon as possible. The program's early (and cheapest) stages must address the most pressing concerns.The earlier in the process that uncertainty is resolved (e.g. by proper risk inference and quantification, careful in vitro and in vivo experiments, modeling and simulation), the better the chances of making subsequent correct developmental decisions—whether to end unsafe or futile compounds or move forward with truly promising compounds.In this setting, biostatisticians give a different and valuable perspective, as they are schooled to assess uncertainty. Preclinical, research, quality, natural history, and clinical trial design and analysis all require rethinking within the specific limitations of a genetic therapy study. Hence, this skill set is in significant demand in the GTx sector. Pharmacometricians, who are physiologically based mathematical modeling specialists and have extra abilities complementing statistical knowledge and expertise, are equally vital players. To manage complex drug development challenges, the two functions, biostatistics and pharmacometry, are increasingly working jointly. Based on our recent experience in this sector, the development of gene therapy drugs presents unique quantitative issues and potential, and collaboration among biostatisticians, pharmacometricians, and other quantitative scientists in this field can produce synergistic results.Because of GTx's unique character and the inherent high level of uncertainty associated with these treatments, incorporating a biostatistician and pharmacometric as early as practical in the GTx development process is crucial.It is vital that multi-domain practitioners—academic, industrial, and regulatory—work together to set standards and best practices and communicate scientific and technological viewpoints from their various groups to support innovation in quantitative drug development of GTx products. Gene therapies have the potential to provide highly focused breakthrough one-time treatment to individuals with considerable unmet medical needs, eliminate the need for maintenance drug schemes, and reduce the danger of off-target side effects. Developing gene therapy is exceedingly complex and unexpected. Quantitative groups will be critical to the success of future gene therapy programs and must approach drug development in this space as fully integrated strategic partners in cross-functional drug development teams, sharing information and learning throughout the preclinical, manufacturing, early design, and late product planning lifecycles. For quantitative teams working on gene therapy research, experience in epidemiological methodologies, bioinformatics, clinical pharmacology, classical experiment design, rare disease clinical trial design, and a deep grasp of the biology underpinning these medicines will be critical skill areas.

scholarly journals Evolution of Clinical Trial Design in Early Drug Development: The Use of Expansion Cohorts (ECS) in Phase I Cancer Trials (PITS)

2012 ◽  
Vol 23 ◽  
pp. ix158
Author(s):  
A. Manji ◽  
I. Brana Garcia ◽  
E. Amir ◽  
I.F. Tannock ◽  
P. Bedard ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Development ◽  
Phase I ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Cancer Trials ◽  
Early Drug
Sign in / Sign up

Export Citation Format

Share Document